WO2011072286A1 - Fils de dispositif biomédical implantable comprenant des conducteurs liquides - Google Patents
Fils de dispositif biomédical implantable comprenant des conducteurs liquides Download PDFInfo
- Publication number
- WO2011072286A1 WO2011072286A1 PCT/US2010/060078 US2010060078W WO2011072286A1 WO 2011072286 A1 WO2011072286 A1 WO 2011072286A1 US 2010060078 W US2010060078 W US 2010060078W WO 2011072286 A1 WO2011072286 A1 WO 2011072286A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lead
- electrically conductive
- conductive composition
- interior lumen
- lumen
- Prior art date
Links
- 239000004020 conductor Substances 0.000 title claims abstract description 167
- 239000007788 liquid Substances 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 claims abstract description 249
- 229910052751 metal Inorganic materials 0.000 claims abstract description 50
- 239000002184 metal Substances 0.000 claims abstract description 50
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229910052733 gallium Inorganic materials 0.000 claims abstract description 42
- 229910045601 alloy Inorganic materials 0.000 claims abstract description 32
- 239000000956 alloy Substances 0.000 claims abstract description 32
- 229910001084 galinstan Inorganic materials 0.000 claims abstract description 19
- 229910000846 In alloy Inorganic materials 0.000 claims abstract description 18
- 229920001940 conductive polymer Polymers 0.000 claims abstract description 12
- 239000007787 solid Substances 0.000 claims description 102
- 239000012212 insulator Substances 0.000 claims description 28
- 206010016654 Fibrosis Diseases 0.000 claims description 23
- 230000000747 cardiac effect Effects 0.000 claims description 20
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 18
- 238000007789 sealing Methods 0.000 claims description 16
- 238000004891 communication Methods 0.000 claims description 12
- 230000006835 compression Effects 0.000 claims description 12
- 238000007906 compression Methods 0.000 claims description 12
- -1 polytetrafluoroethylene Polymers 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 239000012811 non-conductive material Substances 0.000 claims description 9
- 229910052697 platinum Inorganic materials 0.000 claims description 9
- 230000004761 fibrosis Effects 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 238000005452 bending Methods 0.000 claims description 7
- 239000003638 chemical reducing agent Substances 0.000 claims description 7
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 7
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 7
- 239000004812 Fluorinated ethylene propylene Substances 0.000 claims description 6
- 239000002033 PVDF binder Substances 0.000 claims description 6
- 239000004696 Poly ether ether ketone Substances 0.000 claims description 6
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 6
- QXZUUHYBWMWJHK-UHFFFAOYSA-N [Co].[Ni] Chemical compound [Co].[Ni] QXZUUHYBWMWJHK-UHFFFAOYSA-N 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 229920009441 perflouroethylene propylene Polymers 0.000 claims description 6
- 229920002530 polyetherether ketone Polymers 0.000 claims description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 6
- 229910001220 stainless steel Inorganic materials 0.000 claims description 6
- 239000010935 stainless steel Substances 0.000 claims description 6
- 229910052719 titanium Inorganic materials 0.000 claims description 6
- 239000010936 titanium Substances 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000002513 implantation Methods 0.000 claims description 5
- 230000000926 neurological effect Effects 0.000 claims description 5
- 229920002635 polyurethane Polymers 0.000 claims description 5
- 239000004814 polyurethane Substances 0.000 claims description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims description 4
- 238000010168 coupling process Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 229910052709 silver Inorganic materials 0.000 claims description 4
- 239000004332 silver Substances 0.000 claims description 4
- 229910052715 tantalum Inorganic materials 0.000 claims description 4
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims description 4
- 102000005606 Activins Human genes 0.000 claims description 3
- 108010059616 Activins Proteins 0.000 claims description 3
- 102000009840 Angiopoietins Human genes 0.000 claims description 3
- 108010009906 Angiopoietins Proteins 0.000 claims description 3
- 229920000049 Carbon (fiber) Polymers 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- 229920001609 Poly(3,4-ethylenedioxythiophene) Polymers 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 3
- 108010039918 Polylysine Proteins 0.000 claims description 3
- 239000000488 activin Substances 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000006229 carbon black Substances 0.000 claims description 3
- 239000004917 carbon fiber Substances 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 claims description 3
- 238000001125 extrusion Methods 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 239000002085 irritant Substances 0.000 claims description 3
- 231100000021 irritant Toxicity 0.000 claims description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 3
- 239000002121 nanofiber Substances 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 229920000052 poly(p-xylylene) Polymers 0.000 claims description 3
- 229920000553 poly(phenylenevinylene) Polymers 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 229920000767 polyaniline Polymers 0.000 claims description 3
- 229920000656 polylysine Polymers 0.000 claims description 3
- 229920000128 polypyrrole Polymers 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 229920000123 polythiophene Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000010410 layer Substances 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 24
- 229910001338 liquidmetal Inorganic materials 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 17
- 239000000499 gel Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 238000009532 heart rate measurement Methods 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 239000000284 extract Substances 0.000 description 8
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 150000002739 metals Chemical class 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000005611 electricity Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 206010003119 arrhythmia Diseases 0.000 description 3
- 238000012925 biological evaluation Methods 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 238000002788 crimping Methods 0.000 description 3
- 230000002600 fibrillogenic effect Effects 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101100440286 Mus musculus Cntrl gene Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 231100000569 acute exposure Toxicity 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000002763 arrhythmic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229920000249 biocompatible polymer Polymers 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 206010061592 cardiac fibrillation Diseases 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 201000009032 substance abuse Diseases 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000036829 Device dislocation Diseases 0.000 description 1
- 101100284769 Drosophila melanogaster hemo gene Proteins 0.000 description 1
- 229910000807 Ga alloy Inorganic materials 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229910000575 Ir alloy Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 229910001260 Pt alloy Inorganic materials 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000011128 cardiac conduction Effects 0.000 description 1
- 238000013194 cardioversion Methods 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000012777 electrically insulating material Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000010363 phase shift Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01B—CABLES; CONDUCTORS; INSULATORS; SELECTION OF MATERIALS FOR THEIR CONDUCTIVE, INSULATING OR DIELECTRIC PROPERTIES
- H01B7/00—Insulated conductors or cables characterised by their form
- H01B7/0009—Details relating to the conductive cores
- H01B7/0027—Liquid conductors
Definitions
- Heart disease persists as the top cause of death in the United States. There are over 5 million people living with heart disease, with 670,000 new occurrences per year and an annual mortality rate of 266,000. Abnormal rhythm events, or arrhythmias, are often associated with cardiac ischemia or failure. Arrhythmias can by treated by restoring cardiac conduction to a natural rhythm using cardiac rhythm management devices (CRMDs), which administer electrical shocks to the myocardium in response to arrhythmic events.
- CRMDs cardiac rhythm management devices
- CRMDs cardiac pacemakers and implantable cardioverter defibrillators.
- Pacemakers are used to restore and maintain synchrony between the sinoatrial node and the ventricles.
- Implantable cardioverter-defibrillators ICDs are used to restore normal cardiac electrical function during adverse events such as ventricular tachycardia or fibrillation, and to detect adverse events. ICDs can deliver much higher energy electrical impulses than pacemakers.
- ICDs deliver pulses on the order of joules in order to produce widespread cardiac depolarization and the subsequent restoration of normal rhythm, which is in contrast to the microjoule pulses generated by pacemakers. From 1984 to 2000, the rate of ICD implantation increased from 6/100,000 to 12.7/100,000. Approximately 250,000 ICDs are currently implanted per year.
- Conductive leads are used to transmit electrical signals produced by a CRMD to target tissues.
- Standard lead components are: a connector to interface the lead with the stimulating device; conductor(s) that are typically comprised of some electrically conductive metallic material; insulating materials to shield the conductors from each other and the surrounding environment; and terminating electrode(s) with fixation mechanisms for interface with the tissue.
- the electrodes and connectors are often made of conducting, inert metals that exhibit minimal polarization effects, e.g., platinum, stainless steel, MP35N alloy, or titanium.
- Insulators e.g., silicone rubber, polyurethane, or PTFE, encase the conducting materials, electrically isolating the conductor(s) and protecting the lead's functional components from physiological responses in situ.
- the lead may be required to transmit high power signals, such as the 10-20A pulse, in the range of 100-lOOOV typically generated by an implantable cardioverter defibrillator (ICD).
- ICD implantable cardioverter defibrillator
- the leads may also carry small currents, such as those used in neurological stimulators or cardiac pacemakers, which are on the order of milliamps.
- implantable biomedical leads may comprise a single, unipolar lead, or they may comprise a bipolar lead, depending upon the therapy to be applied. Regardless of the device's power output, or its unipolar or bipolar configuration, implantable leads are subjected to significant mechanical and chemical stresses in situ. An implantable lead must be able to withstand those harsh circumstances and maintain their ability to conduct the electrical signals necessary to effectively impart treatment to the target tissue.
- Cardiac rhythm therapy is ineffective if the signals of interest are not transmitted to and from the device due to lead failure.
- Leads in situ are subject to a tremendous range of chemical-immunological and mechanical stresses induced by lead deformation that occurs with 37 million heartbeats per year. Modes of lead failure include conductor fracture, insulation fracture, and lead dislodgement at the myocardium. Lead conductors are usually damaged due to excessive bending, torquing, or crushing of the lead at the proximal or distal end.
- CRMD leads may be implanted between the clavicle and first rib. This position makes the conductors susceptible to compression, creating stress that can eventually lead to breakage.
- Fracture of conductors presents a serious problem because electrical signals may not be transmitted across the large impedances created by a breakage or the device may sense artifacts created by their mechanical motion or by intermittent contact of the separated but solid conductors. Also, the electrical interference from overlying muscles could be interpreted by ICD sensing circuitry as an arrhythmic event, triggering unnecessary ICD shocks and possibly inducing fibrillation or fatal cardiac arrest.
- the outer helical wires are comprised of a different conductor composition than that of the central conductor wire or cable.
- the outer conductor may be a less conductive, but a mechanically stronger material, allowing the many small encapsulating wires to act as an armor plating of sorts that is further able to conduct electrical signals across any small fractures that may develop in the larger, more conductive material below.
- such mixing of conductors can result in stresses due to differing physical characteristics as well, and may further add to stresses developed by tightly coiling a harder metal over a softer, weaker, metal or fiber core.
- the lead comprises a lead body having a distal end and a proximal end, the lead body defining a first interior lumen therethrough, and an electrically conductive composition positioned within the first interior lumen, the electrically conductive composition comprising a metal in a liquid state at or below about 98° F.
- the electrically conductive composition is selected from the group consisting of gallium, a gallium-indium alloy, Galinstan, its/their alloys, and combinations thereof.
- the metallic electrically conductive composition is used along with a second non-metallic electrically conductive composition such as a conductive polymer, an electrically conductive liquid, an electrically conductive gel, or combinations thereof.
- the lead body comprises a non-conductive material selected from the group consisting of silicone, polyurethane, polytetrafluoroethylene (PTFE), ethylene tetraflurooethylene (ETFE), polyether ether ketone (PEEK), perfluroralkoxyethylene- tetrafluoroethylene (PFA), fluorinated ethylene propylene (FEP), polyvinylidene fluoride (PVDF), polyamide, parylene, nylon, co-extrusions thereof, and combinations thereof.
- PTFE polytetrafluoroethylene
- ETFE ethylene tetraflurooethylene
- PEEK polyether ether ketone
- PFA perfluroralkoxyethylene- tetrafluoroethylene
- FEP fluorinated ethylene propy
- the first interior lumen is filled with the electrically conductive composition under vacuum or under atmospheric pressure.
- the electrically conductive composition maintained within the first interior lumen under vacuum or under atmospheric pressure.
- the electrically conductive composition fills the first interior lumen.
- the lead further comprises a distal component coupled to the lead body at or near the distal end of the lead body, the distal component in conductive communication with the electrically conductive composition.
- the distal component is selected from the group consisting of an electrode, a connector, an adapter, a coil, and a closure device.
- the distal component is capable of sealing the distal end of the lead body to prohibit loss of the electrically conductive composition from the first interior lumen and to mitigate entry of bodily fluids into the first interior lumen.
- the lead further comprises a membrane at least partially surrounding the lead body.
- the membrane comprises a biologically-compatible non- conductive material.
- the lead further comprises a solid conductor positioned within the first interior lumen of the lead body.
- the lead further comprises a solid conductor positioned within the first interior lumen of the lead body.
- the solid conductor comprises a conductive material selected from the group consisting of stainless steel, platinum, titanium, silver, tantalum, a nickel-cobalt base alloy, its/their alloys, and combinations thereof.
- the electrically conductive composition and the solid conductor are capable of transmitting a first electrical signal therethrough.
- the electrically conductive composition and the solid conductor are capable of transmitting the first electrical signal in a first direction.
- the electrically conductive composition is capable of transmitting a first electrical signal therethrough, and wherein the solid conductor is capable of transmitting a second electrical signal therethrough.
- the lead further comprises an insulator positioned between the electrically conductive composition and the solid conductor.
- the lead further comprises a second interior lumen defined within the lead body.
- the lead further comprises a solid conductor positioned within the second interior lumen of the lead body, wherein the electrically conductive composition is capable of transmitting a first electrical signal therethrough, and wherein the solid conductor is capable of transmitting either the first electrical signal or a second electrical signal therethrough.
- the electrically conductive composition is capable of transmitting the first electrical signal in a first direction, and wherein the solid conductor is capable of transmitting the second electrical signal in a second direction.
- the solid conductor is selected from the group consisting of an uncoiled wire, a coiled wire, a round wire, a flat wire, a helically turned conductive ribbon, a drawn filled tube wire, a helical hollow strand wire, a drawn brazed strand wire, a cable wire, and a combination thereof.
- the lead further comprises a proximal component coupled to the lead body at or near the proximal end of the lead body, the proximal component in conductive communication with the electrically conductive composition.
- the proximal component is selected from the group consisting of an electrode, a connector, and a closure device.
- the proximal component is capable of sealing the proximal end of the lead body.
- the lead further comprises a biomedical device coupled to the proximal component, the biomedical device capable of transmitting and/or receiving an electrical signal from the electrically conductive composition.
- the biomedical device is selected from the group consisting of a cardiac pacemaker, an implantable cardioverter defibrillator, an electrocardiogram (EKG or ECG) device, and electroencephalogram (EEG) device, a neurological stimulator, and a non-neurological stimulator.
- the lead further comprises a biomedical device coupled to the lead body at or near the proximal end of the lead body, the biomedical device capable of transmitting and/or receiving an electrical signal from the electrically conductive composition and further capable of sealing the proximal end of the lead body.
- the lead further comprises a first interior tube positioned within the first interior lumen, the interior tube defining a first interior tube lumen.
- the lead further comprises a solid conductor, wherein the electrically conductive composition is capable of transmitting a first electrical signal therethrough, and wherein the solid conductor is capable of transmitting a second electrical signal therethrough, wherein the electrically conductive composition is positioned within the first interior lumen external to the first interior tube, and wherein the solid conductor is positioned within the first interior tube lumen.
- the first interior tube comprises a non-conductive insulator.
- the electrically conductive composition is positioned within the first interior tube lumen within the first interior lumen.
- the electrically conductive composition is positioned within the first interior lumen external to the first interior tube, and wherein the first interior tube comprises a conductive material.
- the first interior tube lumen is configured as a stylet lumen.
- the lead further comprises a second interior tube positioned within the first interior tube lumen, the second interior tube defining a second interior tube lumen.
- the electrically conductive composition is positioned within the first interior lumen external to the first interior tube.
- the electrically conductive composition is also positioned within the first interior tube lumen.
- the lead further comprises a solid conductor positioned within the first interior tube lumen, wherein the electrically conductive composition is capable of transmitting a first electrical signal therethrough, and wherein the solid conductor is capable of transmitting a second electrical signal therethrough.
- the second interior tube lumen is configured as a stylet lumen.
- the first interior tube comprises a non-conductive material, and wherein the electrically conductive composition is positioned within the first interior lumen external to the first interior tube.
- the first interior tube lumen is configured as a stylet lumen.
- the lead body further defines a second interior lumen and a third interior lumen.
- the lead further comprises a first solid conductor positioned within the second interior lumen, wherein the electrically conductive composition is capable of transmitting a first electrical signal therethrough, and wherein the first solid conductor is capable of transmitting a second electrical signal therethrough.
- the third interior lumen is configured as a stylet lumen.
- the lead body further defines a fourth interior lumen.
- the electrically conductive composition is also positioned within the second interior lumen and the third interior lumen.
- the electrically conductive composition is also positioned and the fourth interior lumen.
- the lead further comprises a second solid conductor positioned within the third interior lumen, the second solid conductor capable of transmitting a third electrical signal therethrough.
- one or more of the first electrical signal, the second electrical signal, and the third electrical signal are equivalent.
- the lead body further defines a second interior lumen.
- the electrically conductive composition is also positioned within the second interior lumen.
- the lead further comprises a first solid •conductor positioned within the first interior lumen, wherein the electrically conductive composition is capable of transmitting a first electrical signal therethrough, and wherein the first solid conductor is capable of transmitting a second electrical signal therethrough.
- the lead further comprises a second solid conductor positioned within the second interior lumen, the second solid conductor capable of transmitting a third electrical signal therethrough.
- the lead further comprises a first solid conductor capable of transmitting a second electrical signal therethrough, the first solid conductor positioned within the second interior lumen.
- the lead further comprises a doped portion at or near the distal end of the lead body, the doped portion comprising a non-conductive material and a conductive material.
- the conductive material is selected from the group consisting of stainless steel, platinum, titanium, silver, tantalum, a nickel-cobalt base alloy, carbon black, carbon fiber, nanofiber tubes, polyaniline, polypyrrole, polythiophene, polyethylenedioxythiophene, and poly(p-phenylene vinylene).
- the lead further comprises a cuff positioned at least circumferentially around the lead body, the cuff configured to compress at least a portion of the lead body to facilitate coupling of the distal component to the lead body.
- the solid conductor is coated with an insulated coating.
- the distal component defines a circumferential groove separating an outer portion from an inner portion, and wherein the circumferential groove is configured so that the distal end of the lead body fits within the circumferential groove so that the outer portion is on the relative outside of the lead body and so that the inner portion is within the first interior lumen.
- the distal component is sized and shaped as a pin, the pin having an outer perimeter sized and shaped to fit within the first interior lumen.
- the distal component is configured to engage an external electrode.
- the lead body has a cross-sectional area configured so that one or more conductance pockets are defined within the first interior lumen upon compression of the lead body.
- the lead body comprises one or more relatively thinner portions and one or more relatively thicker portions, wherein said one or more relatively thinner portions and the one or more relatively thicker portions define an irregularly-shaped first interior lumen.
- the one or more relatively thicker portions when the lead body is compressed, define one or more conductance pockets therein.
- the lead further comprises at least two solid conductors positioned within the first interior lumen.
- the electrically conductive composition and the at least two solid conductors are capable of transmitting a first electrical signal.
- each of the at least two solid conductors are surrounded by an insulator.
- the electrically conductive composition is capable of transmitting a first electrical signal, and wherein the at least two solid conductors are capable of transmitting a second electrical signal.
- the first interior lumen is configured as a strain relief lumen.
- the lead further comprises one or more strain relief lumens defined within the lead body, the one or more strain relief lumens configured so that upon compression of the lead body, the one or more strain relief lumens compresses before the first interior lumen.
- the lead is capable of transmitting an electrical signal through the electrically conductive composition at a lower resistance than a traditional lead having equivalent dimensions but using only a solid conductor.
- the lead is capable of transmitting an electrical signal through the electrically conductive composition resulting in less signal energy loss in lead impedance through the electrically conductive composition as compared to signal energy losses in lead impedance through a solid conductor of a traditional lead.
- the signal energy losses are due to conduction (i2R) losses through the various leads.
- the first interior lumen comprises a configuration selected from the group consisting of a straight configuration, a twisted configuration, and a coiled configuration.
- the lead is operable as a unipolar lead.
- the lead is operable as a bipolar lead.
- the lead further comprises a second interior lumen and a third interior lumen defined by the lead body, the second interior lumen and the third interior lumen each having the electrically conductive composition and/or a solid conductor positioned therethrough.
- the lead is operable as a multipolar lead.
- the electrically conductive composition is biologically-compatible.
- the electrically conductive composition is non-toxic;
- the first interior lumen has a diameter of between about 0.005" and about 0.108".
- the lead body has a wall thickness of between about 0.005" and about 0.054".
- the lead body has an outer diameter of between about 1 French to about 12 French.
- the lead body has a length between about 10cm and about 200cm.
- the distal component is at least partially coated with a fibrosis-enhancing substance, the fibrosis-enhancing substance capable of facilitating localized fibrosis at or near the distal component upon connection of the lead to a tissue within a patient's body to reduce the likelihood of unintended disconnection of the lead from the tissue.
- the fibrosis-enhancing substance is selected from the group consisting of an irritant, polylysine, high-concentration lysine peptides, growth factors, inflammatory cytokines, activin, and angiopoietin.
- the distal component is at least partially coated with a fibrosis-reducing substance, the fibrosis-reducing substance capable of inliibiting localized fibrosis at or near the distal component upon implantation of the lead within a patient's body to reduce a likelihood of a loss or reduction of an electrical signal through the lead.
- the fibrosis-reducing substance comprises dexamethasone.
- the lead body comprises a material capable of flexion so that repeated bending of the lead body does not result in loss of conductance through the electrically conductive material.
- the electrically conductive composition is sufficiently pliable so to reduce a likelihood of fracture of the lead body at a location where at least a portion of the electrically conductive composition contacts at least a portion of the lead body.
- the lead body is sufficiently flexible and the electrically conductive composition is sufficiently pliable so to reduce a likelihood of tissue perforation within a patient's body when the lead is positioned within the patient's body and coupled to the tissue as compared to a traditional lead having a solid conductor.
- the lead further comprises a second conductor composition positioned within the first interior lumen of the lead body.
- the first electrically conductive composition comprises a metal in a liquid state selected from the group consisting of gallium, a gallium-indium alloy, Galinstan, its/their alloys, and combinations thereof
- the second conductor composition comprises a non-metallic composition selected from the group consisting of a conductive polymer, an electrically conductive liquid, an electrically conductive gel, and combinations thereof.
- the system comprises a lead for use in a biomedical application of the present disclosure, comprising a lead body having a distal end and a proximal end, the lead body defining a first interior lumen therethrough, and an electrically conductive composition positioned within the first interior lumen, the electrically conductive composition comprising a metal in a liquid state at or below about 98° F, and a biomedical device coupled to the lead, the biomedical device capable of transmitting and/or receiving an electrical signal from the electrically conductive composition within the lead.
- the lead comprises a lead body having a distal end and a proximal end, the lead body defining a first interior lumen therethrough; and an electrically conductive composition positioned within the first interior lumen, the electrically conductive composition in a liquid or gel state at or below about 98° F.
- the electrically conductive composition comprises a metal in a liquid state selected from the group consisting of gallium, a gallium-indium alloy, Galinstan, its/their alloys, and combinations thereof.
- the electrically conductive composition is selected from the group consisting of gallium, a gallium-indium alloy, Galinstan, its/their alloys, a conductive polymer, an electrically conductive liquid, an electrically conductive gel, and combinations thereof.
- the electrically conductive composition comprises a first electrically conductive composition and a second electrically conductive composition.
- the first electrically conductive composition comprises a metal in a liquid state selected from the group consisting of gallium, a gallium-indium alloy, Galinstan, its/their alloys, and combinations thereof
- the second electrically conductive composition comprises a non-metallic composition selected from the group consisting of a conductive polymer, an electrically conductive liquid, an electrically conductive gel, and combinations thereof.
- the system comprises a lead for use in a biomedical application of the present disclosure, comprising a lead body having a distal end and a proximal end, the lead body defining a first interior lumen therethrough, and an electrically conductive composition positioned within the first interior lumen, the electrically conductive composition in a liquid or gel state at or below about 98° F, and a biomedical device coupled to the lead, the biomedical device capable of transmitting and/or receiving an electrical signal from the electrically conductive composition within the lead.
- the lead comprises a lead body having a distal end and a proximal end, the lead body defining a first interior lumen therethrough, an electrically conductive composition positioned within the first interior lumen, the electrically conductive composition comprising a metal in a liquid state at or below about 98° F, the electrically conductive composition selected from the group consisting of gallium, a gallium-indium alloy, Galinstan, its/their alloys, and combinations thereof, a distal component coupled to the lead body at or near the distal end of the lead body, the distal component in conductive communication with the electrically conductive composition, the distal component capable of sealing the distal end of the lead body, and a proximal component coupled to the lead body at or near the proximal end of the lead body, the proximal component in conductive communication with the electrically conductive composition, the proximal component capable of sealing the proximal end of the
- the system comprises a lead for use in a biomedical application of the present disclosure, comprising a lead body having a distal end and a proximal end, the lead body defining a first interior lumen therethrough, and an electrically conductive composition positioned within the first interior lumen, the electrically conductive composition comprising a metal in a liquid state at or below about 98° F, the electrically conductive composition selected from the group consisting of gallium, a gallium-indium alloy, Galinstan, its/their alloys, and combinations thereof, a distal component coupled to the lead body at or near the distal end of the lead body, the distal component in conductive communication with the electrically conductive composition, the distal component capable of sealing the distal end of the lead body, and a proximal component coupled to the lead body at or near the proximal end of the lead body, the proximal component in conductive communication with the electrically conductive composition, the proximal component
- the lead body having a distal end and a proximal end, the lead body defining a first interior lumen therethrough, and the lead body configured to contain an electrically conductive composition within the first interior lumen, the electrically conductive composition in a liquid or gel state at or below about 98° F, the lead capable of transmitting a first electrical signal through the electrically conductive composition.
- the system comprises an exemplary lead of the present disclosure and a biomedical device coupled to the lead, the biomedical device capable of transmitting and/or receiving an electrical signal from the electrically conductive composition within the lead.
- FIG. 1 A shows a perspective side view of an exemplary lead according to at least one embodiment of the present disclosure
- FIG. IB shows a side view of an exemplary lead according to at least one embodiment of the present disclosure
- FIGS. 2A-2C show cross-sectional views of exemplary leads according to various embodiments of the present disclosure
- FIGS. 3A and 3B show side views of exemplary leads according to various embodiments of the present disclosure
- FIG. 4A shows a perspective side view of an exemplary lead according to at least one embodiment of the present disclosure
- FIG. 4B shows a side view of an exemplary lead according to at least one embodiment of the present disclosure
- FIGS. 5 A, 5B, and 6 A show cross-sectional views of exemplary leads according to various embodiments of the present disclosure
- FIG. 6B shows a side view of an exemplary lead according to at least one embodiment of the present disclosure
- FIGS. 6C shows a cross-sectional view of an exemplary lead according to at least one embodiment of the present disclosure
- FIGS. 6D, 7 A, and 7B show side views of exemplary leads according to various embodiments of the present disclosure
- FIGS. 8A-10J show cross-sectional views of exemplary leads according to various embodiments of the present disclosure
- FIGS. 11A-11C show perspective side views of exemplary leads having a distal component coupled thereto according to various embodiments of the present disclosure
- FIG. 12 shows a graph showing the voltage measure across an exemplary lead according to at least one embodiment of the present disclosure
- FIG. 13 shows a graph showing the measured step response of an exemplary lead according to at least one embodiment of the present disclosure
- FIG. 14A shows an exemplary set of schematics of circuits used to measure the effects of an exemplary lead according to at least one embodiment of the present disclosure
- FIG, 14B shows pulse measurement with a conventional lead and with an exemplary lead according to at least one embodiment of the present disclosure
- FIG. 15 A shows a graph showing pulse measurements with a conventional lead cross- correlated with pulse measurements of a conventional lead in series with an exemplary lead according to at least one embodiment of the present disclosure
- FIG. 15B shows a graph showing power spectral density estimates from a pacemaker with a conventional lead and with a conventional lead in series with an exemplary lead according to at least one embodiment of the present disclosure
- FIGS. 16A and 16B show microscopic images of cells incubated with an electrically conductive composition used in connection with exemplary leads according to various embodiments of the present disclosure
- FIG. 17A shows a chart displaying mean cell counts from cells exposed to an electrically conductive composition used in connection with exemplary leads of the present disclosure as compared to controls;
- FIG. 17B shows a chart displaying hemocompatibility assay results obtained from testing an exemplary electrically conductive composition of the present disclosure
- FIG. 18 shows a cardiac electrogram obtained using a exemplary lead of the present disclosure.
- lead 100 comprises a lead body 102 having a proximal end 104 and a distal end 106.
- Lead body 102 defines a first outer surface 108 and a first inner surface 110, wherein the first outer surface 108 is on the relative outside of lead body 102, and wherein the first inner surface 110 is the opposing inner surface of first outer surface 108.
- lead body 102 has a tubular shape, defining a first interior lumen 112 therein.
- lumen is defined as a portion within a lead 100 configured to optionally receive and retain a conductor, such as an electrically conductive composition 200 referenced in further detail herein, and is not limited to traditional tubular lumens.
- Leads 100 of the present disclosure comprise various components at or near the proximal ends 104 and the distal ends 106 of said leads.
- lead 100 comprises a proximal component 1 14 at or near the proximal end 104 of lead body 102, and a distal component 1 16 at or near a distal end 106 of lead body 102.
- Components 114, 116 may comprise electrodes, connectors, coils, closure devices, etc., useful not only to seal a/the respective end(s) 104, 106 of said lead body 102, but also, in various embodiments, to prevent bodily fluids from entering lumen 1 12, to perform a function (such as an electrode), to engage a tissue (such as a coil), or to facilitate connection of lead 100 to another component, for example.
- the jagged lines present in the relative centers of leads 100 shown in FIGS. 1A and IB are intended to indicate that leads 100 of the present disclosure can have various lengths.
- Lead body 102 may comprise any number of biologically-compatible non-conductive or conductive components useful for implantable leads.
- lead bodies 102 comprise silicone and/or polyurethane.
- lead bodies 102 (as well as insulators 902, referenced in further detail herein), may comprise, but are not limited to, polytetrafluoroethylene (PTFE), ethylene tetraflurooethylene (ETFE), polyether ether ketone (PEEK), perfluroralkoxyethylene-tetrafluoroethylene (PFA), fluorinated ethylene propylene (FEP), polyvinylidene fluoride (PVDF), polyamide, parylene, nylon, or any number of co-extrusions of said polymers or combinations of said polymers.
- PTFE polytetrafluoroethylene
- ETFE ethylene tetraflurooethylene
- PEEK polyether ether ketone
- PFA perfluroralkoxyethylene-tetrafluoroethylene
- FEP fluor
- portions of various leads 100 of the present disclosure may be coated with a substance 118 to facilitate localized fibrosis.
- distal component 116 could optionally have a fibrosis-enhancing substance 118, such as a steroid, positioned thereon so that local fibrosis at the location of adherence of distal component 116 to a heart would be expedited, as such localized fibrosis can help maintain a secure connection of lead 100 to the heart.
- a fibrosis-enhancing substance 118 is selected from the group consisting of an irritant, poly lysine, high- concentration lysine peptides, growth factors, inflammatory cytokines, activin, and angiopoietin.
- distal component 116 is at least partially coated with a fibrosis-reducing substance 1 18, such as dexamethasone, for example, which is capable of inhibiting localized fibrosis at or near distal component 116 upon implantation of lead 100 within a patient's body to reduce a likelihood of a loss or reduction of an electrical signal through lead 100.
- Leads 100 of the present disclosure may be relatively long and narrow.
- various leads 100 of the present disclosure may have a lead body 102 thiclcness of about 0.005" (or even less) to about 0.108", and lead 100 outer diameters as large as about 12 French (about 0.1 18").
- Various leads may have lumen diameters as small as about 0.0165", or within a range of about 0.005" to about 0.108".
- various leads 100 of the present disclosure may have outer diameters between about 1 French to about 12 French.
- various leads 100 of the present disclosure may have various lead body 102 lengths. In at least one embodiment, lead body 102 has a length of approximately 50cm. In other embodiments, lead bodies 102 may have lengths between 10cm and 200cm.
- Various other lumen 1 12 diameters, lead body 102 thicknesses, lead 100 outer diameters, and lead body 102 lengths may be present in any number of leads 100 of the present disclosure, as the exemplary sizes and ranges provided herein are merely exemplary in nature, noting that various lead 100 embodiments may have dimensions outside of said ranges.
- an exemplary embodiment of a lead 100 of the present disclosure may comprise a first electrode (an exemplary proximal component 114) in sealable contact with the proximal end 104 of lead body 102, and may further comprise a second electrode (an exemplary distal component 1 16) in sealable contact with the distal end 106 of lead body 102.
- FIG. 2A shows a cross-sectional view of an exemplary lead 100 of the present disclosure along section A--A 1 as shown in FIG. IB.
- operable leads 100 of the present disclosure comprise an electrically conductive composition 200 present within first interior lumen 112 and/or another lumen as may be the case with one or more embodiments of leads 100 of the present disclosure.
- Electrically conductive composition 200 as shown in FIG. 2A, may be depicted as a series of diagonal lines.
- exemplary electrically conductive compositions 200 of the present disclosure may comprise liquid metal, such as, for example, gallium, a gallium-indium alloy, Galinstan, its/their alloys, and combinations thereof, having a melting point at or below 98° F (approximate mammalian body temperature) or otherwise being a liquid or a gel at or below 98° F.
- Various other electrically conductive compositions 200 of the present disclosure may comprise non-metallic electrically conductive polymers, liquids, and/or gels, having a melting point at or below 98° F or otherwise being a liquid or a gel at or below 98° F.
- Various embodiments of leads 100, using electrically conductive compositions 200 of the present disclosure are operable for use in various sensing and pacing applications as referenced herein.
- electrically conductive composition 200 may readily disengage itself from tube body 102, or may tend to remain in contact with tube body 102, the latter generally referred to as a wetting property of electrically conductive composition 200, Wetting may be desired or undesired depending upon application, and as such, suitable materials may be selected to produce tube body 102, for example, to correspond with said desired application.
- Electrically conductive compositions 200 provide a means of conducting a signal/electricity within lead 100.
- a lead 100 of the present disclosure as shown in FIG. IB may have an electrically conductive composition 200 positioned within lumen 1 12 so that electrically conductive composition 200 is capable of conducting a signal/electricity between proximal component 114 and distal component 1 16.
- the dotted lines represent the first inner surface 110 of lead 100.
- leads 100 of the present disclosure may comprise a conductor wire 202 positioned within the first interior lumen 112 of lead 100 or within another portion/component of lead 100.
- Conductor wire 202 in embodiments of leads having at least one conductor wire 202, may provide another means of conducting a signal/electricity within lead 100 along with an electrically conductive composition 200 positioned within said lead 100, thereby creating a redundancy of the conductive properties of lead 100 and providing additional rigidity to lead 100. This exemplary redundancy and rigidity help to prevent lead body 102 from kinking and causing a separation between any of the electrically conductive composition 200 that would preclude conduction of any therapeutic electrical impulses.
- Conductor wire 202 in various embodiments, may be any solid conductor currently used in connection with various biomedical leads, and may comprise uncoiled wire, a coiled wire, a round wire, a flat wire, a helically turned conductive ribbon, a drawn filled tube wire, a helical hollow strand wire, a drawn brazed strand wire, a cable wire, a combination thereof, or another suitable solid conductor.
- conductor wire 202 (also referred to as a solid metal component/layer 904 referenced in further detail herein) may have a coating thereon, such as an insulator 902 described in further detail herein, so that electrically conductive composition 200 and conductor wire 202 / solid metal component/layer 904 can carry separate signals.
- FIG. 2C shows another cross-sectional view of an exemplary lead 100 of the present disclosure.
- Lead 100 shows the same components as the cross- sectional view of lead 100 shown in FIG. 2B, but without the electrically conductive composition 200 included therein.
- Such an embodiment could be filled with an electrically conductive composition 200 to produce a lead 100 as shown in FIG. 2B.
- the exemplary embodiment of lead 100 shown in FIG. 2C comprises a membrane 204 surrounding at least part of lead body 102.
- membrane 204 may be used to insulate a conductive portion of lead 100 from a bodily tissue, for example.
- FIGS. 3 A and 3B show exemplary embodiments of a lead 100 and a system of the present disclosure comprising an exemplary lead.
- lead 100 comprises a proximal component 114 coupled to lead 100 at or near the proximal end 104 of lead 100, and comprises a distal component 116 coupled to lead 100 at or near the distal end 106 of lead 100.
- lead 100 is coupled to a biomedical device 300, with said coupling occurring between biomedical device 300 and proximal component 1 14.
- 3A may be viewed as a lead 100 coupled to a biomedical device 300, or may be considered as a system 350 of the present disclosure, wherein system 300 comprises a lead 100 of the present disclosure and some other component, such as, for example, biomedical device 300.
- a signal and/or electricity may be transmitted to or from biomedical device 300 to a proximal component 114, through an electrically conductive composition 200 present within lead body 102, and to a distal component 116.
- proximal component 114 may be a connector or an adapter (or component of a connector or adapter) to connect lead 100 to biomedical device 300
- distal component 116 may be an electrode, a connector, a coil, and/or a closure device, for example.
- FIG. 3B shows another exemplary embodiment of a lead 100 coupled to a biomedical device 300.
- lead 100 is coupled to a biomedical device 300 at or near the proximal end 104 of lead 100, and lead 100 comprises a distal component 1 16 coupled to lead 100 at or near the distal end 106 of lead 100.
- biomedical device 300 is the effective proximal component.
- An external component 310 may be coupled to distal component 116, so that a signal transferred through lead 100 can be carried through distal component 116 to external component 310.
- distal component 116 may be a connector
- external component 310 may be an electrode (which may be referred to as an "exposed electrode"), a connector, and/or a closure device, for example.
- electrical signals may be transmitted through lead 100 through electrically conductive composition 200 from biomedical device 300 to electrode distal component 116 (such as an electrode, for example), thereby causing therapeutic stimulation of a remote target tissue adjacent to distal component 116.
- electrode distal component 116 such as an electrode, for example
- various leads 100 of the present disclosure utilize an electrically conductive composition 200 having a melting point at or below 98° F (or otherwise being a liquid or a gel at or below 98° F) such that the conductor is a liquid and thereby significantly less susceptible to fracture.
- electrically conductive composition 200 is contained within first interior lumen 112 of lead 100, which effectively maintains a continuous liquid conduction path from biomedical device 300 to distal component 116 (such as an electrode, for example).
- first interior lumen 112 (or one or more other lumens of the present disclosure) is filled with electrically conductive composition 200 under vacuum or under atmospheric pressure.
- electrically conductive composition 200 is maintained under vacuum or under atmospheric pressure.
- leads 100 are prepared in a way to prevent gaseous pockets (bubbles) from forming within electrically conductive composition 200 which can disrupt the ability of lead 100 to conduct a signal from biomedical device 300 to distal component 116, and vice versa.
- electrically conductive composition 200 may comprise a conductive polymer, an electrically conductive liquid, metal, alloy, etc. as described herein, with an appropriate conductivity and resistivity to allow conduction of an appropriate electric current over the required length of biomedical device lead 100 and to administer a therapeutic current to a target tissue.
- alloys and metals that may be utilized as electrically conductive compositions 200 may include, but are not limited to, gallium, its alloys (such as gallium-indium alloys, for example), Galinstan, a conductive polymer, an electrically conductive liquid, an electrically conductive gel, or combinations thereof.
- electrically conductive composition 200 is biologically-compatible (or non-toxic), so that in the unlikely event of lead 100 breakage, electrically conductive composition 200 will not have a detrimental effect to the patient. It will be appreciated that the resistivity of gallium or its alloys may exceed that of common biomedical device wire materials such as MP35N, 35N LT, or similar alloys, platinum or iridium alloys, copper, gold, or platinum. However, liquid metal alloy-based leads may exhibit a larger cross-sectional areas than large gauge, helically wound solid metal conductors often utilized to reduce fracturing, thereby decreasing the overall resistance of the lead, and allowing electric currents to be transmitted through a lower resistance path than that utilized in conventional implantable biomedical leads.
- an electrically conductive composition suspended in liquid or gel form may further comprise the electrically conductive composition 200, and any such electrically conductive liquid wire less than 20 ohms of resistance, for example, may be utilized as a conductor for low current applications, e.g.
- implantable or external cardiac pacemakers while electrically conductive solutions having no more than 1 ohm, and optionally no more than .5 ohms (500 milliohms) of resistivity may be utilized for high current applications, e.g. , an implantable cardioverter defibrillator.
- high current applications e.g. , an implantable cardioverter defibrillator.
- low current applications such as pacing stimulation
- those currents may be transferred by solutions having a relatively high resistance, depending upon the cross-section of the lead required as well as the overall length.
- Medium current applications such as neural stimulation have intermediate requirements.
- Various leads 100 of the present disclosure may be used with implantable or external cardiac pacemakers for treatments of cardiac arrhythmias, cardioverter/defibrillators for delivering cardio version/defibrillation shocks to a distal electrode, as a neural stimulator lead, or for various other implantable or external electrical stimulator/measurement device lead applications, such as applications in connection with electrocardiogram (EKG or ECG) devices and electroencephalogram (EEG) devices, for example.
- EKG or ECG electrocardiogram
- EEG electroencephalogram
- Each said component may be viewed as an exemplary biomedical device 300 of the present disclosure. Accordingly, and as referenced generally herein, various leads 100 of the present disclosure can be used with various sensing and stimulating biomedical devices 300, conducting electrical signals to and from said devices 300.
- FIGS. 4A and 4B At least another exemplary embodiment of a lead 100 of the present disclosure is shown in FIGS. 4A and 4B.
- lead 100 ' comprises a lead body 102 having a proximal end 104 and a distal end 106, and defining a first outer surface 108 and a first inner surface 1 10.
- lead 100 effectively comprises a "double sheath," as lead 100 has a second sheath, identified generally as interior tube 400, positioned within first interior lumen 112 defined by lead body 102.
- Interior tube 400 as shown in FIG.
- FIG. 4A has a proximal end 402 and a distal end 404, and itself defines a second outer surface 406 and a second inner surface 408, with interior tube 400 further defining a second interior lumen 410 therein (surrounded by second inner surface 408).
- FIG. 4B shows a side view of an exemplary lead 100 of the present disclosure having a double sheath.
- the dotted lines represent the internal walls of lead 100, namely first outer surface 108, first inner surface 110, second outer surface 406, and second inner surface 408.
- lead 100 may comprise a proximal component 114 at or near the proximal end 104 of lead body 102, and may comprise a distal component 116 at or near the distal end 106 of lead body 102.
- FIG. 5 A shows cross-sectional views of lead 100 along section B--B' as shown in FIG. 4B.
- operable leads 100 of the present disclosure comprise an electrically conductive composition 200 present within either first interior lumen 112 and/or second interior lumen 410 as may be the case with one or more embodiments of leads 100 of the present disclosure.
- Electrically conductive composition 200 is depicted as a series of diagonal lines
- FIG. 5B shows a cross-sectional view of another embodiment of a lead 100 of the present disclosure, comprising a conductor wire 202 positioned within first interior lumen 112 and another conductor wire 202 positioned within second interior lumen 410.
- leads 100 may have one or more conductor wires 202 positioned within first interior lumen 112, second interior lumen 410, and/or embedded within lead body 102 and/or tube 400 itself. Said conductor wires 202, in various embodiments, could coil within first interior lumen 1 12 around second interior lumen 410.
- first interior lumen 1 12 and/or second interior lumen 410 may be filled with, or otherwise be in fluid contact with, electrically conductive composition 200.
- Lead body 102 and/or tube 400 may themselves comprise a polymer or other material compatible with the selected electrically conductive composition 200, or portions thereof may be covered with a polymer or other material compatible with the electrically conductive composition 200.
- an effective outer sheath of lead 100 may substantially encapsulate an effective interior sheath, with one or both comprising or covered with a polymer or other material compatible with the electrically conductive composition 200.
- electrically conductive compositions 200 of the present disclosure may themselves be corrosive or caustic to certain other materials, creation of such a dual-sheath, as shown in FIGS. 4A-5B, allows for biocompatibility along with longevity of lead 100.
- leads 100 of the present disclosure may be unipolar, namely that lead 100 has one physical connection to another device, such as a pacemaker, for example.
- lead 100 may be used to connect a device to a heart, whereby the return path of the circuit flows through the body.
- an electrical signal can be transmitted to or from the heart, and the patient's body completes the circuit.
- Such an embodiment may be used for a sensing application, for example.
- leads 100 of the present disclosure may be bipolar, meaning that lead 100 has two physical connections to another device, such as a pacemaker, forming a cathode and an anode, for example.
- lead 100 may be used to connect a device to a heart, whereby the return path of the circuit flows through the lead 100.
- an electrical circuit can be completed by sending a signal to the heart through one conductor and sending a return signal from the heart using a second conductor.
- various leads 100 of the present disclosure may be multipolar, which is defined herein as having three or more conductor paths. In such an embodiment, such as the leads 100 shown in FIGS.
- signals can be sent to and from a heart using lead 100, and such signals, for example, can be redundant using two or more lead conductors.
- Such an embodiment may be used for a sensing application and a pacing application, for example, given the two physical conductors within said lead 100.
- lead 100 comprises a lead body 102 having four channels/lumens.
- said lumens comprise first interior lumen 112, second interior lumen 410, third interior lumen 600, and fourth interior lumen 602, each defined within lead body 102.
- One or more of said lumens 112, 410, 600, 602 may be filled with an electrically conductive composition 200 as described herein, and depending on configuration of lead 100, signals may be transmitted in a first direction (indicated by the (+) shown in FIG. 6A) and in a second direction (indicated by the (-) shown in FIG. 6A).
- the two (+) identifiers and the two (-) identifiers in FIG. 6A indicate either redundant conductor paths with signals flowing in opposite directions, or two separate conductor paths with signals flowing in one direction and two separate conductor paths with signals flowing in an opposite direction.
- FIG. 6B shows a side view of at least a portion of lead 100 of the present disclosure that could be used as a bipolar lead 100.
- lead 100 comprises a lead body, with two lumens (selected from 112, 410, 600, and 602, with 112 and 410 selected in the present example).
- Distal component 1 16, shown in FIG. 6B may comprise a coil configured to permanently or removably engage a targeted tissue.
- a cuff 604 may be positioned at least partially circumferentially around lead 100, said cuff 604 configured, in at least one embodiment, to compress at least a portion of lead 100 so that a distal component 116 remains affixed thereto.
- Said embodiment, as well as other bipolar or multi-lumen (multipolar) leads 100 of the present disclosure may be referred to herein as having redundant conductors.
- FIGS. 6C and 6D show additional embodiments of leads 100 of the present disclosure that could also be used as bipolar leads 100.
- FIG. 6C shows a cross-sectional view of lead 100, comprising a lead body 102 and three lumens (selected from 112, 410, 600, and 602, with 1 12, 410, and 600 selected in the present example).
- FIG. 6D shows a side view of at least a portion of lead 100 shown in FIG. 6C, wherein lumen 112 is configured as a stylet lumen, and wherein lumens 410 and 600 are filled with an electrically conductive composition 200 to conduct signals to and from the respective ends 104, 106 of lead 100.
- lumen 410 could be filled with a solid conductor
- lumen 112 could be filled with an electrically conductive composition 200.
- Stylet lumens of various embodiments of leads 100 of the present disclosure may be configured to allow a stylet to be positioned therethrough, whereby the stylet can be used to deliver lead 100 (or portions thereof) to a desired location within a body, for example, and/or used to engage portions of lead 100 to facilitate engagement of lead 100 components (such as distal component 116, for example), at a desired location within a body and/or to engage an electrode, for example.
- Lead 100 as shown in FIG. 6D, may have three distal components 116 comprising coils and/or electrodes as shown therein.
- FIGS. 7 A and 7B show additional embodiments of exemplary leads 100 of the present disclosure.
- FIG. 7A shows at least part of an exemplary lead 100 of the present disclosure having a doped portion 700 at or near distal end 106 of lead 100,
- Doped portion 700 in various embodiments, comprises a conductive material 702 embedded therein, so that a signal transmitted through an electrically conductive composition 200 within lead body 102 may further be transmitted through doped portion 700 and optionally any distal component 116 adjacent thereto.
- conductive material 702 is comprised of, but not limited to, stainless steel, platinum, titanium, silver, tantalum, MP35N (an exemplary nickel- cobalt base alloy), 35N LT (another exemplary nickel-cobalt base alloy), carbon black, carbon fiber, nanofiber tubes, polyaniline, polypyrrole, polythiophene, polyethylenedioxythiophene, poly(p-phenylene vinylene), and/or other materials useful to maintain electrical conductivity.
- FIG. 7B shows an exemplary embodiment of a lead 100 of the present disclosure having a conductor wire 202 positioned therein, similar to the embodiment of lead 100 shown in FIGS. 2B and 2C.
- the embodiment of lead 100 shown in FIG. 7B has a coiled conductor wire 202 positioned therein, wherein said conductor wire 202 is coated by insulated coating 704.
- a first signal may be transmitted through an electrically conductive composition 200 within lead 100
- a second signal may be transmitted through conductor wire 202.
- electrically conductive composition 200 and conductor wire 202 could both be used to transmit the same (or redundant) signal through lead 100.
- lead 100 may comprise a distal component 116, and in at least one embodiment, conductor wire 202 may be positioned through distal component 116 so that a non-coated portion of conductor wire 202 is exposed at a distal end 106 of lead 100.
- a first signal may travel through electrically conductive composition 200 to distal component 1 16 (a sensing electrode, for example), and a second signal may travel through conductor wire 202 to a targeted tissue adjacent to the exposed portion of conductor wire 202 of lead 100.
- FIGS. 8 A, 8B, and 8C show various configurations of first interior lumens 112 of exemplary leads 100 of the present disclosure.
- lead 100 defined a first interior lumen 112 having a modified pentagonal cross-section.
- Such an embodiment could allow for relatively thicker portions of lead body 102 to exist along with relatively thinner portions of lead body 102 so that, for example, lead 100 is not only structurally sound but also flexible as needed/desired for a particular application, and so that lead 100 may maintain active conductance in the event of compression.
- various lumens 410, 600, 602, and others can be more readily defined within the relatively thicker portions of lead body 102, so that such lumens can include a conductor or provide stylet access, for example.
- Lead bodies 102 of the present disclosure are not limited to the circular and modified pentagonal cross-sections as described and shown herein, as various other embodiments, such as hexagonal, septagonal, octagonal, and others may be used depending on the desired application.
- FIG. 8B The cross-sectional view of the exemplary lead 100 of the present disclosure shown in FIG. 8B shows a lead body 102 having a coiled first interior lumen 112 defined therethrough.
- a first interior lumen 112 defined within lead body 102 can be filled with an electrically conductive composition 200, so that for a given length of lead 100 and diameter of first interior lumen 112, more electrically conductive composition 200 would be present in an embodiment of lead 100 having a coiled first interior lumen 112 instead of a straight first interior lumen 1 12.
- FIG. 8C shows a cross-sectional view of another exemplary embodiment of a lead 100 of the present disclosure.
- lead 100 comprises a lead body 102 having relatively thick and relatively thin portions which define an irregular star-shaped lumen 112.
- Such an embodiment may provide additional strength to lead body 102, may provide the physical cross-sectional area to add one or more additional lumens within lead body 102, and so that lead 100 may maintain active conductance in the event of compression.
- the irregularly-shaped lumen 112, defined by lead body 102 results in lead body 102 having one or more relatively thinner portions 800 and one or more relatively thicker portions 802.
- FIG. 8D shows a perspective cross-sectional view of an exemplary lead 100 of the present disclosure that has been compressed.
- lead body 102 is defined the same as or somewhat similar to lead 100 shown in FIG. 8 A, and compression thereof forms localized conductance pockets 804 that, if first interior lumen 1 12 filled with an electrically conductive composition 200, conductance can be maintained through said lead 100 in the event of compression/bending as conductance pockets 804 would not fully close.
- a conductance pockets 804 may be formed when two relatively thicker portions 802 of lead body 102 engage one another.
- an exemplary lead 100 comprises the following layers/elements as viewed from the outside of lead 100 to the relative center of lead 100: a lead body 102, a first interior lumen 112, a first interior tube 400 (the wall of said tube 400), a second interior lumen 410 (defined within first interior tube 400), a second interior tube 900 (the wall of said tube 900), and a third interior lumen 600.
- first interior tube 400 and second interior tube 900 may either or both be viewed as insulators, effectively insulating portions of lead 100 from one another.
- first interior lumen 112 and second interior lumen 410 may be filled with an electrically conductive composition 200, and third interior lumen 600 may serve as a stylet lumen, for example, at the relative middle/center of lead 100.
- FIG. 9B shows a cross-section of an exemplary lead 100 of the present disclosure having the following layers/elements as viewed from the outside of lead 100 to the relative center of lead 100: a lead body 102, a solid metal component/layer 904, a non-conductive insulator 902, a first interior lumen 112, a first interior tube 400 (the wall of said tube 400), and a second interior lumen 410 (defined within first interior tube 400).
- first interior lumen 1 12 may be filled with an electrically conductive composition 200, and second interior lumen 410 may serve as a stylet lumen, for example, at the relative middle/center of lead 100.
- FIG. 9C shows a cross-section of another exemplary lead 100 of the present disclosure having the following layers/elements as viewed from the outside of lead 100 to the relative center of lead 100: a lead body 102, a first interior lumen 1 12, an insulator 902 (or a first interior tube 400 (the wall of said tube 400)), a solid metal component/layer 904, and a second interior lumen 410 (defined within solid metal component/layer 904).
- first interior lumen 112 may be filled with an electrically conductive composition 200
- second interior lumen 410 may serve as a stylet lumen, for example, at the relative middle/center of lead 100.
- FIG. 9D shows a cross-section of an exemplary lead 100 of the present disclosure having two lumens 112, 410 for placement of an electrically conductive composition 200 therein.
- lead 100 has the following layers/elements as viewed from the outside of lead 100 to the relative center of lead 100: a lead body 102, a first interior lumen 112, an insulator 902 (or a first interior tube 400 (the wall of said tube 400)), and a second interior lumen 410 (defined within insulator 902 or first interior tube 400).
- first interior lumen 112 and second interior lumen 410 may be filled with an electrically conductive composition 200 so that such an embodiment of lead 100 may operate as a bipolar lead if desired.
- Lead 100 may be designed and/or used as bipolar leads 100 as generally referenced herein.
- lead 100 comprises both a cathode (a negative terminal, typically active) and an anode (a positive terminal, typically inactive or return).
- the creation of a cathode and anode is accomplished by infusing a liquid metal into a sheath of biocompatible, electrically insulating material, forming the active electrode.
- the inactive electrode typically the anode, is optionally encapsulated either concentrically or co-longitudinally with the active electrode.
- the active electrode defined by electrically conductive composition 200 within the first interior lumen 1 12
- the active electrode is surrounded by a larger diameter, electrically insulating, biocompatible sheath (namely, tube body 102).
- the space between the inner and outer sheaths namely lead body 102 and insulator 902/first interior tube 400
- is filled with the liquid metal electrically conductive composition 200 effectively forming a coaxial liquid wire as shown in FIG. 9D.
- said lead 100 embodiment as well as various other lead embodiments 100 having multiple poles / lumens, may be less susceptible to pinching/ldnlcs when in use, which may cause potential leakage of electrically conductive composition 200 and/or a loss of conductivity within lead 100.
- two columns of liquid metal will be encapsulated in biocompatible, electrically insulating polymer sheaths, as shown in FIG. 6B, for example.
- the liquid columns namely the first interior lumen 112 and the second interior lumen 410 filled with electrically conductive composition 200, are optionally placed in a larger diameter biocompatible polymer sheath (namely lead body 102), with the columns longitudinal axes parallel to each other.
- the liquid columns may be twisted into a pair.
- the columns are optionally surrounded by an additional insulator 902, and an additional port, namely a third interior lumen 600, included therein to facilitate lead placement via a semi-rigid stylus (a stylet), as shown in the exemplary embodiment shown in FIG. 6C.
- an additional insulator 902 and an additional port, namely a third interior lumen 600, included therein to facilitate lead placement via a semi-rigid stylus (a stylet), as shown in the exemplary embodiment shown in FIG. 6C.
- FIG. 10A Another exemplary lead 100 of the present disclosure is shown in FIG. 10A.
- lead 100 has the following layers/elements as viewed from the outside of lead 100 to the relative center of lead 100: a lead body 102, a first interior lumen 112, an insulator 902 (or a first interior tube 400 (the wall of said tube 400)), and a solid metal component/layer 904 at the relative center of lead 100, said solid metal component/layer 904 also being referred to as a conductor wire 202, as shown in FIG. 2B and described herein.
- An electrically conductive composition 200 may be placed within first interior lumen 102 so that such an embodiment of lead 100 may also operate as a bipolar lead if desired.
- lead 100 uses potentially redundant current paths, namely a first path using an electrically conductive composition 200 and a second path using a solid metal component/layer 904.
- the electrically conductive composition 200 is used in conjunction with conventional implanted lead materials.
- the conventional solid lead assembly is not altered; liquid metal (the electrically conductive composition 200) is instead infused and in direct contact with the solid metal conductor (solid metal component/layer 904).
- Both materials are encapsulated by an insulating, biocompatible polymer, namely lead body 102 and insulator 902, for example, as shown in FIG. 10A.
- the liquid metal conductor thereby acts as an alternate conduit, providing a low impedance path for current to be transmitted in the event of solid conductor fracture.
- FIG. 10B shows a cross-section of yet another exemplary lead 100 of the present disclosure
- lead 100 has the following layers/elements as viewed from the outside of lead 100 to the relative center of lead 100: a lead body 102, a solid metal component/layer 904, an insulator 902 (or a first interior tube 400 (the wall of said tube 400)), and a first interior lumen 112 for containing an electrically conductive composition 200.
- FIG. IOC shows a cross-section of an additional embodiment of a lead 100 of the present disclosure.
- first interior lumen 112 (and/or other lumens 410, 600, 602, or others) may be non-conductive or clad with a thin coating of a conductive material (such as a conductive material 702 used with doped ends of various leads 100 or metals used in solid metal component layers 904 of the present disclosure), thereby allowing conduction of electrical signals throughout the surface of said lumen 112 (or other lumens) and be in contact with an electrically conductive composition 200.
- a conductive material such as a conductive material 702 used with doped ends of various leads 100 or metals used in solid metal component layers 904 of the present disclosure
- FIGS. 10D and 10E show cross-sectional views of additional embodiments of leads 100 of the present disclosure.
- lead 100 comprises two solid metal components/layers 904 therein, so that if first interior lumen 112 is filled with an electrically conductive composition 200, lead 100 would carry a redundant signal through electrically conductive composition 200 and solid metal components/layers 904. If the solid metal components/layers 904 were coated with an insulator 902, as shown in FIG. 10E, separate signals could be transmitted through electrically conductive composition 200 and solid metal components/layers 904.
- FIGS. 10F and 10G show exemplary lead 100 embodiments with four solid metal components/layers 904, without insulators 902 (FIG.
- FIG. 10F shows an exemplary lead 100 embodiment with eight solid metal components/layers 904 coated with insulators 902.
- FIGS. 101 and 10J show cross-sections of exemplary embodiments of leads 100 of the present disclosure with crescent-shaped lumens.
- lead body 102 defines a first interior lumen 112 and a second interior lumen 410, whereby said lumens 1 12, 410 have a cross-sectional shape with a relatively wide portion terminating at both ends to a point.
- FIG. 10J shows an exemplary lead 100 embodiment with four lumens, whereby lumens 112 and 410 are strain relief lumens, and 600 and 602 are regular lumens.
- One or more such lumens 112, 400, 600, 602 may be filled with an electrically conductive composition 200 as referenced within the present disclosure, whereby electrically conductive composition 200 confirms to the various shapes of said lumens.
- electrically conductive composition 200 confirms to the various shapes of said lumens.
- the overall flexibility of various leads 100 of the present disclosure including the use of a electrically conductive composition 200 that is capable of deforming and confirming to lumen(s) of said leads 100, may obviate the need for additional compression lumens.
- an exemplary distal component 116 of the present disclosure may comprise a distal component 116 having a circumferential groove 1 100 defined therein, so that an outer portion 1102 of distal component 116 may positioned on the relative outside of lead body 102, and so that an inner portion 1104 of distal component 116 may be positioned in the relative inside of lead body 102.
- lead body 102 itself is sized and shaped to fit within circumferential groove 1100 of distal component 116, so that distal component 116 effectively seals the distal end 106 of lead body 102.
- FIGS. 11B and 11C show exemplary distal components 116 of the present disclosure configured as pins.
- distal component 116 is pin-shaped, so that distal component has an outer perimeter sized and shaped to fit within a first interior lumen 112 of a lead body 102, effectively sealing the distal end of lead body 102.
- Distal component 116 in various embodiments, may have an adhesive 1106 positioned thereon and/or an adhesive 1 106 may be positioned within first interior lumen 112 so that distal component 116 may more effectively seal the distal end 106 of lead body 102. As shown in FIG.
- a cuff 604 may also be positioned around lead body 102, whereby cuff 604 exerts pressure against lead body 102 (by way of the configuration of cuff 604 and/or by crimping cuff 604 against lead body 102) to facilitate sealing of the distal end 106 of lead body 102 along with distal component 116.
- Such compression may be a localized crimping, or may involve swaging, namely a full concentric pinch to fully concentrically compress cuff 604 around lead body 102.
- various proximal components 114 of the present disclosure may be configured as the various distal components 116 shown in FIGS. 1 lA-11C are configured.
- Embodiments of leads 100 without metals as compared to embodiments of leads 100 comprising metal(s) may have different applications.
- various embodiments of leads 100 with and without metals may have different conductivity capabilities, different relative lives, different perforation capabilities (as less rigid leads 100 are less capable of tissue perforation as compared to more rigid leads 100), potential dislodgment rates, pliabilities, and the ability to produce leads 100 of various sizes.
- various leads 100 of the present disclosure solve for three main lead failures, namely conductor failure, insulator failure, and perforation failure.
- Conductor failure is solved by way of using an electrically conductive composition 200 with or without a redundant solid metal conductor, in various embodiments.
- Insulator failure is solved by designing leads 100 whereby the conductive portions are properly matched to the insulative portions, namely lead body 102 and other insulators. By filling various lumens of leads 100 with an electrically conductive composition 200 that conforms to the lumen shape(s), leads 100 can maintain conductivity even in the event of significant bending or crimping of said leads 100.
- Perforation failure is also solved as various leads 100 of the present disclosure can have superior flexibility, allowing for additional bending as needed, as well as relatively larger cross-sectional areas as the electrically conductive composition 200, as noted below, has excellent impedance properties so that less power is needed to conduct a signal therethrough as compared to traditional leads as various leads 100 of the present disclosure have a lower resistance as compared to traditional leads.
- Such physical embodiments decrease the potential for incidences of myocardial perforation, as perforation rates increase when leads of relatively small cross-sectional areas are used.
- relatively thick and relatively flexible leads are less likely to cause myocardial perforation as compared to relatively thin and relatively stiff leads.
- leads 100 are capable of transmitting an electrical signal through electrically conductive composition 200 at a lower resistance than a traditional lead having equivalent dimensions but using only a solid conductor.
- lead 100 is capable of transmitting an electrical signal through electrically conductive composition 200 resulting in less signal energy loss in lead impedance through electrically conductive composition 200 as compared to signal energy losses in lead impedance through a solid conductor of a traditional lead.
- ICD leads typically have a resistance of 2 ⁇ - 8 ⁇ , and load impedance at the tissue-electrode interface of 50 ⁇ . The comparable impedances between the load and lead can result in significant energy drops across the lead, reducing overall efficiency of the ICD.
- an ICD delivering electrical stimuli through a 6.8 ⁇ lead resistance and a 50 ⁇ termination resistance will lose at least 12% of the pulse energy due to conduction 2R) losses through the lead.
- a lead 100 of the present disclosure with a 120 mQ (bipolar) lead resistance for example, it is predicted that 0.2% of the signal energy would be lost in the lead impedance, significantly increasing the energy efficiency of the ICD.
- lead body 102 comprises a material capable of flexion so that repeated bending of lead body 102 does not result in loss of conductance through electrically conductive material 200.
- electrically conductive composition 200 is sufficiently pliable so to reduce a likelihood of fracture of lead body 102 at a location where at least a portion of electrically conductive composition 200 contacts at least a portion of lead body 102.
- lead body 102 is sufficiently flexible and electrically conductive composition 200 is sufficiently pliable so to reduce a likelihood of tissue perforation within a patient's body when lead 100 is positioned within the patient's body and coupled to the tissue as compared to a traditional lead having a solid conductor.
- leads 100 may comprise a metallic electrically conductive composition 200, such as gallium, a gallium- indium alloy, Galinstan, its/their alloys, or combinations thereof, as well as a non-metallic electrically conductive composition 200, such as a conductive polymer, an electrically conductive liquid, an electrically conductive gel, or combinations thereof.
- a metallic electrically conductive composition 200 such as gallium, a gallium- indium alloy, Galinstan, its/their alloys, or combinations thereof
- a non-metallic electrically conductive composition 200 such as a conductive polymer, an electrically conductive liquid, an electrically conductive gel, or combinations thereof.
- a unipolar liquid metal lead 100 was developed by infusing liquid gallium (Ga 4N, Recapture Metals) into a polyurethane tube.
- the tube dimensions were comparable to those of a conventional cardiac pacing lead, having a length of 610mm and an inner diameter of 1.7mm.
- the tube was filled with Ga such that the lumen appeared free of any voids and terminated on each end with segments of 22 AWG solid core wire.
- the resultant liquid lead 100 was connected to a bipolar amplifier (Kepco BOP100-2M) operating in a constant current mode.
- a sinusoidal voltage was applied across lead 100 and RL and the voltage across the liquid lead (Voa) was measured.
- the frequency of the sinusoidal voltage was increased from DC to 10 kHz, and the voltage of lead 100 was examined to determine whether lead 100 impedance changed as function of frequency.
- VG CI was approximately the same at all frequencies, indicating that lead 100 was a primarily resistive element, as there was no discernible phase shift between the input voltage and the voltage across lead 100 at any frequency of interest. This is beneficial because lead 100 will behave as a low impedance resistor, and therefore signals transmitted through lead 100 will not be distorted in amplitude or phase.
- FIG. 12 shows a graph showing the voltage measured across an exemplary Ga-filled liquid metal lead 100 (VG O ) of the present disclosure, referenced to DC (VG O )- The normalized voltage was near unity at all frequencies of interest, indicating that exemplary lead 100 behaved as low impedance resistive element.
- the transient and steady state response of the aforementioned lead 100 was further examined by exciting the liquid lead- RL network with a step voltage input.
- the circuit was excited with a 4V step input and the output was measured across the load resistor to display any distortive effects from the lead 100.
- the measured voltage across RL almost exactly mirrored the input voltage, as shown in the graph within FIG. 13, indicating again that the impedance of lead 100 does not introduce any significant phase or amplitude distortion on the signal delivered to a load.
- the graph shown in FIG. 13 demonstrates the step response of the exemplary liquid metal lead 100 of the present disclosure in series with load resistor.
- the output voltage, VL was measured across the load resistance of 10.5 ⁇ and compared to the input voltage Vs.
- exemplary lead 100 of the present disclosure was connected to an implantable cardiac pacemaker (an exemplary biomedical device 300 of the present disclosure).
- the pacemaker Medtronic Enpulse Dual Chamber Rate Response Pacemaker
- the liquid wire lead 100 was connected in series with the pacing lead and the load resistance, as shown in the diagrams depicted in FIG. 14 A. It was expected that, because the lead 100 was previously demonstrated to be low impedance resistive element, the output from the conventional lead in series with the lead 100 of the present disclosure would be a faithful reproduction of the signal with the conventional lead alone.
- FIG. 14A shows an exemplary set of schematics of circuits used to measure the effects of an exemplary lead 100 of the present disclosure on output from (a) a cardiac pacemaker (an exemplary biomedical device 300) with conventional lead, and (b) a cardiac pacemaker with a conventional lead in series with a liquid metal lead 100 of the present disclosure.
- the pacemaker pulse measurement with the liquid wire (lead 100) resulted in an accurate reproduction of an identical signal sent through a conventional lead alone, as shown in the graphs in FIG. 14B.
- the graph shown in FIG. 14B demonstrates pulse measurements from a pacemaker with a conventional lead (w/o wire) and with a conventional lead in series with a liquid metal lead 100 of the present disclosure (Ga Wire).
- the pulse of the conventional lead alone was cross-correlated with the pulse measurement with the exemplary lead 100 of the present disclosure.
- the resultant cross-correlation coefficient had a unity value at a lag value of 0, indicating that there was no delay or waveform distortion due to the presence of the liquid metal conductor, as shown in the graph shown in FIG. 15 A.
- the graph shown in FIG. 15A displays a correlation from pulse measurement with conventional lead alone cross-correlated with pulse measurement from conventional lead in series with liquid metal lead 100 of the present disclosure. Additionally, the power spectra of the pulse measurements with and without the liquid metal lead 100 were highly similar, as shown in the graph in FIG. 15B, which shows a power spectral density estimates from pacemaker with conventional lead (w/o wire) and with conventional lead in series with liquid metal lead 100 of the present disclosure (Ga Wire).
- the exemplary unipolar liquid metal lead 100 used in the foregoing tests referenced above shows a very low impedance resistive element, with lead 100 showing the ability to behave as a liquid wire.
- the exemplary lead 100 embodiment displays operates to any phase or amplitude distortion that occurs with signal transmission.
- the prototype liquid metal lead 100 was successfully incorporated with a conventional implantable stimulator, namely a cardiac pacemaker, proving that a refined version of a lead 100 could have some biomedical utility without sacrificing the integrity of signal transmission.
- the biocompatibility of liquid Ga for use as an electrically conductive composition 200 within a biomedical device lead 100 was examined by exposure of Ga to cells in vitro,
- Cells including human umbilical vein endothelial cells (HUVECs), were cultured on tissue culture plastic in fully supplemented growth media.
- the cells were cultured at two densities, namely 170E3 cell/well and 85E3 cells/well, and Ga droplets were added to each well to determine whether acute Ga exposure would affect cell viability and proliferation (control cells did not receive Ga droplets). While such exposure is not representative of any immunological response to implanted Ga, this result suggests that in vitro exposure will have no effect on cell survival or growth.
- the cells tested according to at least one exemplary embodiment were in direct contact with sterilized liquid Ga for 24h and 48h in a 37° C, 5% C0 2 high humidity incubators.
- the cells were then microscopically examined post-Ga exposure. Aside from regions where the liquid metal was initially deposited on the cell wells, there was no evident adverse effect of Ga on the cell monolayers. Cells in direct contact and proximate to the Ga droplets appeared normal and healthy.
- FIGS. 16A and 16B show microscopic images of cells (using a 4x objective) cultured at 170E3 with exposure to Ga (dark regions) at 24 hours (FIG. 16 A) and 48 hours (FIG. 16B) post exposure. The cells were detached and counted to quantify the effects of the Ga. These results, in conjunction with the microscopic images shown in FIGS. 16A and 16B, indicate that acute exposure to Ga did not have an adverse effect on human endothelial cells in vitro, which indicates compatibility with a biological system and demonstrating an appropriate conductor material for an implantable lead.
- lead 100 when using a lead 100 according to at least one embodiment of the present disclosure, is compatible with magnetic resonance imaging ("MRI"). According to at least one exemplary embodiment of a lead 100 of the present disclosure, lead 100 did not distort or reduce the ability to image surrounding tissues or lead 100 itself, and is thereby compatible with allowing imaging of a patient having a lead 100 of the present disclosure without degrading or otherwise interfering with the imaging process.
- MRI magnetic resonance imaging
- liquid gallium was intracutaneously injected into rabbits to examine the acute inflammatory response to gallium exposure.
- the study was conducted in accordance with ISO 10993-10, 2002, Biological Evaluation of Medical Devices - Part 10 and ISO 10993-12, 2007, Biological Evaluation of Medical Devices - Part 12.
- the gallium was injected on the rabbits' anterior sides, while the control material was injected on the posterior sides.
- the injection sites were marked with histology ink.
- the animals were weighed immediately prior to injections and 72 hours post- injection.
- the rabbits were sacrificed by injection of a barbiturate.
- the injection sites were excised and fixed in 10% neutral buffered formalin.
- the tissues were sectioned into histological slides. Slides were stained with hematoxylin and eosin (H&E).
- H&E hematoxylin and eosin
- the male's pre-dose temperature was 39.0 °C, mean post-dose temperature was 39.2 °C ⁇ 0.320 °C.
- the female's pre-dose temperature was 39.4 °C, mean post-dose temperature was 39.5 °C ⁇ 0.208 °C.
- the male's weight decreased by 110 mg over the post-injection time, while the female's weight increased by 80 mg.
- the overall mean scores for the gallium injection and control injection sites were both 0.0 ⁇ 0.0. Macroscopic examination of the tissue sections did not exhibit gross evidence of inflammation, encapsulation, hemorrhage, necrosis, or discoloration. However, microscopic examination in gallium tissue samples from both animals displayed punctate black particles near the injection sites.
- the percent hemolysis of the gallium samples were 0.00% above the level of hemolysis exhibited by the negative control, indicating that direct, acute exposure to gallium is not hemolytic.
- the blood contents of interest included WBC (white blood cell count), RBC (red blood cell count), FIgB (hemoglobin concentration), Hct (hematocrit), MCV (mean corpuscular volume), MCH (mean corpuscular hemoglobin), MCHC (mean corpuscular hemoglobin concentration), and Platelets (platelet count).
- a pacing lead containing liquid gallium as a sole conductor (an exemplary lead 100 of the present disclosure) can successfully stimulate myocardial contractions.
- the stimulatory capability of a unipolar lead 100 prototype was tested in an open chest swine model, whereby lead 100 was connected to a pacemaker (Medtronic E2DR01 Dual Chamber Rate Responsive Pacemaker) operating in VOO mode.
- the terminal electrode of lead 100 was sutured to the epicardium of the right and the left ventricles of the test subject, and the subject's cardiac electrogram was monitored via a sensing electrode placed in the epicardium.
- the swine's intrinsic heart was measured at 72 bpm.
- the disclosure may have presented a method and/or process as a particular sequence of steps.
- the method or process should not be limited to the particular sequence of steps described.
- Other sequences of steps may be possible. Therefore, the particular order of the steps disclosed herein should not be construed as limitations of the present disclosure.
- disclosure directed to a method and/or process should not be limited to the performance of their steps in the order written. Such sequences may be varied and still remain within the scope of the present disclosure.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrotherapy Devices (AREA)
Abstract
La présente invention concerne des fils de dispositif biomédical implantable comprenant des conducteurs liquides. Dans un mode de réalisation d'un fil donné à titre d'exemple pour être utilisé dans une application biomédicale de la présente invention, le fil comprend un corps de fil doté d'une extrémité distale et d'une extrémité proximale - ledit corps de fil définissant une première lumière intérieure à travers le corps - et une composition électriquement conductrice positionnée dans la première lumière intérieure - ladite composition électriquement conductrice comprenant un métal dans un état liquide à une température égale ou inférieure à environ 98° F. Dans un autre mode de réalisation, la composition électriquement conductrice est choisie dans le groupe constitué du gallium, d'un alliage de gallium-indium, du galinstan, de ses/leurs alliages, et de combinaisons de ceux-ci. Dans divers modes de réalisation, la composition métallique électriquement conductrice est utilisée avec une seconde composition non-métallique électriquement conductrice telle qu'un polymère conducteur, un liquide électriquement conducteur, un gel électriquement conducteur, ou des combinaisons de ceux-ci.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/514,926 US20130006339A1 (en) | 2009-12-11 | 2010-12-13 | Implantable biomedical device leads comprising liquid conductors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28570609P | 2009-12-11 | 2009-12-11 | |
US61/285,706 | 2009-12-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011072286A1 true WO2011072286A1 (fr) | 2011-06-16 |
Family
ID=44145951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/060078 WO2011072286A1 (fr) | 2009-12-11 | 2010-12-13 | Fils de dispositif biomédical implantable comprenant des conducteurs liquides |
Country Status (2)
Country | Link |
---|---|
US (1) | US20130006339A1 (fr) |
WO (1) | WO2011072286A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2907541A1 (fr) * | 2014-02-13 | 2015-08-19 | BIOTRONIK SE & Co. KG | Dispositif et procédé de détection de panne de connexion |
EP4092688A1 (fr) * | 2021-05-18 | 2022-11-23 | Nexans | Conduite électrique et procédé de fabrication de la conduite électrique |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150024490A (ko) | 2013-08-26 | 2015-03-09 | 삼성전자주식회사 | 열에 의하여 치유 및 재성형이 가능한 전도성 하이드로겔 복합재료 |
EP3041568B1 (fr) * | 2013-09-06 | 2023-04-26 | MED-EL Elektromedizinische Geräte GmbH | Électrode d'implant cochléaire à alliage métallique liquide |
CN106648259B (zh) * | 2017-01-09 | 2020-07-03 | 京东方科技集团股份有限公司 | 一种触摸屏的制备方法、触摸屏和显示装置 |
WO2018181386A1 (fr) | 2017-03-27 | 2018-10-04 | 株式会社クラレ | Film de résine de polyacétal de vinyle pour verre feuilleté |
CN112216437A (zh) * | 2019-07-11 | 2021-01-12 | 西南民族大学 | 一种基于液态金属和棉线的复合柔性导线及其制备方法 |
WO2023049408A1 (fr) * | 2021-09-23 | 2023-03-30 | The Regents Of The University Of California | Capteur de pression auto-alimenté activé par magnétoélasticité géante pour biosurveillance |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3361865A (en) * | 1965-12-27 | 1968-01-02 | Ibm | Coaxial micro probe |
US4161704A (en) * | 1977-01-21 | 1979-07-17 | Uniform Tubes, Inc. | Coaxial cable and method of making the same |
US5533958A (en) * | 1993-06-17 | 1996-07-09 | Wilk; Peter J. | Intrapericardial assist device and associated method |
US5720724A (en) * | 1988-02-29 | 1998-02-24 | Scimed Life Systems, Inc. | Intravascular catheter with distal guide wire lumen and transition member |
US20020042643A1 (en) * | 1999-07-13 | 2002-04-11 | Cardiac Pacemakers, Inc. | Ring electrode with porous member |
US20030060801A1 (en) * | 2001-09-05 | 2003-03-27 | Colin Chong | Barrier catheter apparatus and method |
US20050154454A1 (en) * | 2003-11-10 | 2005-07-14 | Angiotech International Ag | Intravascular devices and fibrosis-inducing agents |
US7229437B2 (en) * | 2003-09-22 | 2007-06-12 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Medical device having integral traces and formed electrodes |
US20090171336A1 (en) * | 2007-12-26 | 2009-07-02 | Boston Scientific Scimed, Inc. | Catheters and manufacturing thereof |
US7569626B2 (en) * | 2003-06-05 | 2009-08-04 | Dfine, Inc. | Polymer composites for biomedical applications and methods of making |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5248312A (en) * | 1992-06-01 | 1993-09-28 | Sensor Electronics, Inc. | Liquid metal-filled balloon |
US7395120B2 (en) * | 2004-08-13 | 2008-07-01 | The General Hospital Corporation | Telescoping, dual-site pacing lead |
EP1827583B1 (fr) * | 2004-12-22 | 2013-01-23 | Proteus Digital Health, Inc. | Structures hermetiquement scellees implantables |
US8103359B2 (en) * | 2007-05-17 | 2012-01-24 | Cardiac Pacemakers, Inc. | Systems and methods for fixating transvenously implanted medical devices |
US8332049B2 (en) * | 2008-03-31 | 2012-12-11 | Boston Scientific Neuromodulation Corporation | Implantable multi-lead electric stimulation system and methods of making and using |
US8249721B2 (en) * | 2009-07-13 | 2012-08-21 | Boston Scientific Neuromodulation Corporation | Method for fabricating a neurostimulation lead contact array |
-
2010
- 2010-12-13 US US13/514,926 patent/US20130006339A1/en not_active Abandoned
- 2010-12-13 WO PCT/US2010/060078 patent/WO2011072286A1/fr active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3361865A (en) * | 1965-12-27 | 1968-01-02 | Ibm | Coaxial micro probe |
US4161704A (en) * | 1977-01-21 | 1979-07-17 | Uniform Tubes, Inc. | Coaxial cable and method of making the same |
US5720724A (en) * | 1988-02-29 | 1998-02-24 | Scimed Life Systems, Inc. | Intravascular catheter with distal guide wire lumen and transition member |
US5533958A (en) * | 1993-06-17 | 1996-07-09 | Wilk; Peter J. | Intrapericardial assist device and associated method |
US20020042643A1 (en) * | 1999-07-13 | 2002-04-11 | Cardiac Pacemakers, Inc. | Ring electrode with porous member |
US20030060801A1 (en) * | 2001-09-05 | 2003-03-27 | Colin Chong | Barrier catheter apparatus and method |
US7569626B2 (en) * | 2003-06-05 | 2009-08-04 | Dfine, Inc. | Polymer composites for biomedical applications and methods of making |
US7229437B2 (en) * | 2003-09-22 | 2007-06-12 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Medical device having integral traces and formed electrodes |
US20050154454A1 (en) * | 2003-11-10 | 2005-07-14 | Angiotech International Ag | Intravascular devices and fibrosis-inducing agents |
US20090171336A1 (en) * | 2007-12-26 | 2009-07-02 | Boston Scientific Scimed, Inc. | Catheters and manufacturing thereof |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2907541A1 (fr) * | 2014-02-13 | 2015-08-19 | BIOTRONIK SE & Co. KG | Dispositif et procédé de détection de panne de connexion |
US9681816B2 (en) | 2014-02-13 | 2017-06-20 | Biotronik Se & Co. Kg | Device and method for lead failure detection |
EP4092688A1 (fr) * | 2021-05-18 | 2022-11-23 | Nexans | Conduite électrique et procédé de fabrication de la conduite électrique |
Also Published As
Publication number | Publication date |
---|---|
US20130006339A1 (en) | 2013-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20130006339A1 (en) | Implantable biomedical device leads comprising liquid conductors | |
US9750944B2 (en) | MRI-conditionally safe medical device lead | |
EP3156100B1 (fr) | Bobine de plomb compatible irm | |
EP1545694B1 (fr) | Procede de formation d'un conducteur d'electrode de dispositif medical implantable | |
US8666512B2 (en) | Implantable medical device lead including inner coil reverse-wound relative to shocking coil | |
US8825179B2 (en) | Implantable medical device lead including a unifilar coiled cable | |
WO2011049684A1 (fr) | Electrode de tachycardie compatible avec l'irm | |
US8442657B2 (en) | Stimulation and sensing lead with non-coiled wire construction | |
US20210106838A1 (en) | Medical device with braided tubular body | |
US20120123489A1 (en) | Energy storage element design and configuration for implantable intravascular device | |
US9211406B2 (en) | MRI compatible implantable lead |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10836800 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13514926 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10836800 Country of ref document: EP Kind code of ref document: A1 |